Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Prelude Therapeutics Inc (NASDAQ:PRLD) has announced data from the dose-escalation portions of Phase 1 trials of PRT543 and PRT811.
- The data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
- PRT543 demonstrated target engagement and inhibition of PRMT5 functional activity, evidenced by a 69% reduction in serum symmetric dimethylarginine (sDMA) at a dose of 45 mg/5x per week.
- One complete response (CR) was maintained for over 18 months in a patient with HRD+ ovarian cancer.
- Stable disease (SD) persisting for over six months was seen in five patients, including four with adenoid cystic carcinoma (ACC) and one with uveal melanoma.
- The most common grade 3 or higher treatment-related adverse events were thrombocytopenia (27%) and anemia (12%), reversible upon treatment interruption.
- PRT811 demonstrated dose-dependent inhibition of PRMT5 activity, evidenced by an 83% reduction in serum sDMA at 600 mg daily.
- PRT811 demonstrated signs of preliminary clinical activity, including an IDH1 mutated GBM patient who experienced a partial response (PR) that evolved into a durable CR for more than 13 months.
- One patient with splicing-mutant (SF3B1) uveal melanoma demonstrated SD for more than six months with a 25% tumor regression and remains on treatment.
- One additional patient (800 mg twice daily) with SF3B1 uveal melanoma had an unconfirmed PR and 47% decrease in target lesion.
- A patient with triple-negative breast cancer (800 mg QD) demonstrated a 27% decrease in target lesions.
- Related: Why BofA Is Turning Bullish On Prelude Therapeutics.
- Price Action: PRLD stock is down 33.3% at $19.20 during the market session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!